Abstract
• Glaucoma is the leading cause of irreversible blindness in the world, with approximately 8.4 million people blind from glaucomaSlowing disease progression and preservation of quality of life are the main goals for glaucoma treatment.• The only applied proven method to treat glaucoma is the reduction of intraocular pressure• Current glaucoma therapies include topical and systemic drugs, laser surgery, invasive glaucoma surgeries.• The new Micropulse Trans scleral Cyclophotocoagulation (MPTSCPC) is a non-incisional, noninvasive LASER treatment for glaucomaThe micropulse delivery mode includes on and cycles, allowing energy to build up in the targeted pigmented tissues, eventually reaching the coagulative threshold. The adjacent non-pigmented structures have time to cool during the off cycle, thus never reaching the coagulative threshold, which minimizes collateral tissue damageAim of workThe aim of this study is to evaluate the efficacy and safety of contact transscleral micropulse diode cyclophotocoagulation in patients with glaucoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
